Revenue: As of FY2026 Q1, the actual value is USD 12.13 M, beating the estimate of USD 11.97 M.EPS: As of FY2026 Q1, the actual value is USD -0.32, missing the estimate of USD -0.2733.EBIT: As of FY2026 Q1, the actual value is USD -7.447 M.<h4>Total Revenue</h4>ClearPoint Neuro, Inc. reported total revenue of $12,128 thousand for the three months ended March 31, 2026, representing a 43% increase from $8,485 thousand in the same period of 2025, including $2.3 million of IRRAflow revenue . The company achieved 16% year-over-year total organic growth and 25% organic growth in Devices . For the year ended December 31, 2025, ClearPoint Neuro, Inc.’s revenue was $37.0 million .<h4>Segment Revenue</h4><ul><li>Biologics and drug delivery revenue: Increased slightly to $4,800 thousand for the three months ended March 31, 2026, from $4,700 thousand in the prior year .</li><li>Neurosurgery navigation, therapy and access revenue: Increased by 80% to $5,900 thousand for the three months ended March 31, 2026, compared to $3,300 thousand in the same period of 2025, driven by additional revenues from IRRAflow product sales and the introduction of the 3.0 operating room navigation software .</li><li>Capital equipment and software revenue: Increased by 177% to $1,400 thousand for the three months ended March 31, 2026, up from $500 thousand in the same period of 2025, due to increased placements of ClearPoint navigation capital and software, IRRAflow control units, and Prism laser units .</li></ul><h4>Operational Metrics</h4><ul><li>Gross margin: Expanded to 64% for the three months ended March 31, 2026, up from 60% in the same period of 2025, primarily due to lower excess and obsolete inventory . As of March 31, 2026, the gross margin was 62% .</li><li>Operating expenses: Were $16,200 thousand for the three months ended March 31, 2026, a 44% increase from $11,300 thousand in the prior year, mainly due to higher personnel costs from the IRRAS acquisition and increased occupancy and travel costs .</li><li>Operating loss: Was -$8,478 thousand for the three months ended March 31, 2026, compared to -$6,163 thousand for the same period in 2025 .</li><li>Net loss: Was -$9,552 thousand for the three months ended March 31, 2026, compared to -$6,026 thousand for the same period in 2025 .</li></ul><h4>Cash Flow</h4><ul><li>Cash and cash equivalents: Totaled $35,593 thousand as of March 31, 2026, down from $45,923 thousand at December 31, 2025 . This decrease resulted from the use of $8.0 million in cash for operating activities and $2.0 million for taxes related to the net share settlement of equity awards . Cash and cash equivalents were $35.6 million as of March 31, 2026 .</li><li>Net cash flows from operating activities: Were -$7,967 thousand for the three months ended March 31, 2026, compared to -$6,172 thousand in the prior year .</li><li>Net cash flows from investing activities: Were -$645 thousand for the three months ended March 31, 2026, compared to -$183 thousand in the prior year .</li><li>Net cash flows from financing activities: Were -$1,845 thousand for the three months ended March 31, 2026, compared to -$1,362 thousand in the prior year .</li><li>Cash paid for interest: Was $525 thousand for the three months ended March 31, 2026 .</li></ul><h4>Unique Metrics</h4><ul><li>The activated installed base across all ClearPoint technology, including IRRAflow systems, now includes over 175 global centers . The installed base has grown to more than 175 active global centers .</li><li>ClearPoint Neuro, Inc. achieved measurable revenue and cost synergies through the continuing integration of the IRRAflow product portfolio and team .</li><li>ClearPoint Neuro, Inc. has over 170 employees worldwide and holds more than 130 patents issued .</li><li>The company has invested over $100 million in capital over the past 5 years and more than $200 million over the past 15 years .</li><li>Its platform has been utilized in over 10,000 procedures to date and holds regulatory approvals in 34 countries .</li><li>ClearPoint Neuro, Inc. has over 60 active pharma partners, with more than 10 programs accepted for FDA expedited review, and 25+ active clinical trials .</li></ul><h4>Outlook / Guidance</h4>ClearPoint Neuro, Inc. estimates its revenue for 2026 to be between $52.0 million and $56.0 million . The company anticipates that cost synergies from the IRRAS acquisition will reduce cash burn in the second half of 2026, with the integration potentially being cash neutral for the full year 2027 . ClearPoint Neuro, Inc. expects its four-pillar growth strategy to contribute double-digit growth in 2026 and aims for $200 million in annual revenue by winning 20% of an existing $1.0 billion global market opportunity, with a goal of reaching cash breakeven and profitability .

ClearPoint Neuro | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 12.13 M